Sandoz plans 2030 US launch for Ozempic generic

Sandoz, a Swiss pharmaceutical firm, plans to launch a generic version of the diabetes and weight loss drug, semaglutide, in the US in 2030. The company will first introduce the generic in Canada in 2026 after the patent for semaglutide expires. Sandoz is collaborating with Pharmathen for this venture.